Skip to search formSkip to main contentSkip to account menu

Varlilumab

A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B…
Background: The DIAL study is testing the efficacy of dual immunomodulation in patients with advanced aggressive B cell non… 
2019
2019
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B…
TPS7570 Background: The DIAL study is testing the efficacy of dual immunomodulation in patients with advanced B cell non-Hodgkin… 
2018
2018
Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
3001Background: Preclinical studies demonstrate synergistic antitumor activity of PD-1 blockade and varli, a CD27 agonist… 
2017
2017
Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.
3007Background: A phase 1 trial to assess the safety and immunological activity of the combination of varlilumab (V) and… 
2017
2017
Varlilumab Is Safe and Active in Patients with Advanced Solid Tumors.
Varlilumab activates the CD27 pathway in T cells to promote antitumor activity in solid tumors. 
2016
2016
CDX-1140, a Novel Agonist CD40 Antibody with Potent Anti-Lymphoma Activity
CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, is essential for activating both innate and adaptive… 
2016
2016
Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways…
Preclinical studies have demonstrated synergistic antitumor activity when combining PD-1 blockade and varlilumab, a CD27 agonist… 
2015
2015
The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent
The use of agonist antibodies to costimulatory receptors holds significant promise as a complementary approach to the already… 
2015
2015
Abstract 253: Synergistic antitumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site
Varlilumab (CDX-1127) is a fully human agonist antibody to CD27, a TNF receptor superfamily member expressed on the majority of T… 
2014
2014
Immune correlates of varlilumab (CDX-1127) treated cancer patients are consistent with CD27 costimulatory activity
Varlilumab is a human IgG1 agonist anti-CD27 antibody designed to activate T cells through CD27 costimulation. Preclinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)